Advances in the management of peritoneal mesothelioma

doi:10.3748/wjg.v20.i33.11700

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 33

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13032)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

543

WORD

298

HTML

9688

Figures (1-1)

164

Tables (1-3)

167

Sum=10860

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1086

Download

1086

Sum=2172

Sep 7, 2014 (publication date) through Sep 19, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 7, 2014; 20(33): 11700-11712
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11700

Full Size Figure Download Figure

Figure 1 Role of sphingosine 1-phosphate in peritoneal mesothelioma. Inflammation is critical to the development of peritoneal and sphingosine 1-phosphate (S1P) plays an essential role linking it to cancer. Targeting S1P, therefore, with agents like the pro-drug FTY-720 may suppress this process.

Citation: Raza A, Huang WC, Takabe K. Advances in the management of peritoneal mesothelioma. World J Gastroenterol 2014; 20(33): 11700-11712
URL: https://www.wjgnet.com/1007-9327/full/v20/i33/11700.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i33.11700